Goldman Sachs initiated coverage on Silence Therapeutics (NASDAQ:SLN), currently trading at $4.92 with a market cap of $232.3 million, with a Sell rating and a price target of $6.00. According to ...
Researchers found that gut microbiome composition is strongly linked to metabolic health across different life stages, with ...
LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has ac ...
Uncertainty regarding the effectiveness and safety of intensive low-density lipoprotein cholesterol (LDL-C) reduction in ...
Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...
Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...
About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...
Individuals with cutaneous lupus erythematosus have an increased ASCVD risk when compared with those without cutaneous lupus erythematosus.
Among older adults and adults with low atherosclerotic cardiovascular disease risk, use of aspirin decreased after 2019.
This is crucial for evaluating lipid metabolism disorders and assessing atherosclerotic cardiovascular disease (ASCVD) risk ...
NEW equations, named AROSE, have been developed to better predict the 10-year risk of atherosclerotic cardiovascular disease ...
About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback